article thumbnail

How life sciences benefits from broader healthcare transformation

Bio Pharma Dive

Digital transformation has much to offer life sciences as well as healthcare — and the synergies between the two can further optimize the power of digital health, clinical trials and patient outcomes.

article thumbnail

Life science investment outlook: thinking beyond the pandemic

Bio Pharma Dive

Learn about the investment landscape for life science companies, heading into 2023.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Digital dilemma in UK’s life sciences job market

Pharmaceutical Technology

In this issue: Digital jobs in UK life sciences, generative AI changes drug discovery, and how robotics is impacting gene therapy manufacturing.

article thumbnail

Forbion raises $1.47bn for two life sciences-focused funds

Pharmaceutical Technology

European life sciences venture capital firm Forbion has raised €1.35bn ($1.47bn) across its two new funds. The Forbion Growth Opportunities Fund II provides support to the expansion of late-stage life sciences companies. The latest fundraising brings the total funds managed by the company to €3bn ($3.28bn).

article thumbnail

Implementing value-based care to drive success for life sciences companies

Bio Pharma Dive

Value-focused solutions can help life sciences groups make the switch to value-based contracting.

article thumbnail

FABA’s life sciences innovation cluster works on global partnerships to propel novel biologics & diagnostics

AuroBlog - Aurous Healthcare Clinical Trials blog

Federation of Asian Biotech Associations’ (FABA) Life Sciences Innovation Cluster is now working to strengthen the global partnerships to propel an ecosystem for novel biologics and diagnostics.

article thumbnail

Tiziana Life Sciences plans to assess intranasal foralumab for long Covid

Pharmaceutical Technology

Biotechnology company Tiziana Life Sciences has revealed plans to assess intranasal foralumab as a potential treatment for long Covid. Tiziana Life Sciences chief medical officer Matthew Davis said: “We anticipate entering into a Phase 2a placebo-controlled clinical trial upon successful feedback from the FDA.